Telix at ANZSNM Annual Scientific Meeting 2024

Melbourne (Australia) | 23 April 2024

Telix today announces five oral abstract presentations featuring the Company’s late-stage theranostic programs at the 54th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM ASM 2024), being held in Christchurch (New Zealand) from 26-28 April 2024. 

Presentations cover: TLX591 (177Lu rosopatamab tetraxetan), Telix’s lead investigational radio antibody-drug conjugate (rADC) therapy for prostate cancer; Illuccix® (68Ga-PSMA-11), Telix’s approved PET imaging agent for prostate cancer; and TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®1), Telix’s investigational PET imaging agent for kidney cancer.  

In addition, we are pleased to host a Breakfast Session on the latest innovations in theranostics and once again support the Nurses Workshop in collaboration with the Prostate Cancer Foundation of Australia (PCFA), NeuroEndocrine Cancer Australia (NECA) and the Peter MacCallum Cancer Centre in Melbourne. 

Come and meet with us in person at booths 29 and 30 to discuss Telix’s extensive late-stage theranostic pipeline in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning, our associated medical devices and artificial intelligence (AI), along with opportunities for collaboration. 

Details of ANZSNM ASM 2024 abstract presentations related to Telix programs are listed below and the full congress program can be accessed here. 

Title: Lutetium-177 labelled anti-PSMA monoclonal antibody (TLX591, 177Lu rosopatamab tetraxetan) therapy for metastatic prostate cancer: real-world data on treatment toxicity and outcomes 

Presenter: Hanh Nguyen, Fiona Stanley Hospital (Perth, Western Australia) 

Date and Time: Friday 26 April, 2024 | 5:00 pm – 5:15 pm (NZT) 

Session: Therapy Session 

Format: Oral Presentation 

Location: Te Pae Auditorium 

Title: Characterising prostate cancer risk with 68Ga‑PSMA-11 (Illuccix®) PET/CT imaging and AI 

Presenter: Simon Wail, Telix Pharmaceuticals 

Date and Time: Saturday 27 April, 2024 | 12:15 pm – 12:30 pm (NZT) 

Session: Physics Session 

Format: Oral Presentation 

Location: Dobson 4 

Title: Successful use of 68Ga-PSMA-11 for prostate cancer imaging at an Australian imaging centre 

Presenter: Alexis Dalagiorgos, Jones Radiology (Adelaide, South Australia) 

Date and Time: Saturday 27 April, 2024 | 2:30 pm – 2:45 pm (NZT) 

Session: Oncology Session 

Format: Oral Presentation 

Location: Dobson 1 

Title: Safety, tolerability, and dosimetry of TLX591 with best standard of care in patients with PSMA-expressing metastatic castration resistant prostate cancer (ProstACT SELECT) 

Presenter: Nat Lenzo, Nuclear Oncologist and General Internal Medicine Physician (Perth, Western Australia) 

Date and Time: Saturday 27 April, 2024 | 2:45 pm – 3:00 pm (NZT) 

Session: Oncology Session 

Format: Oral Presentation 

Location: Dobson 1 ID: NCT04786847 

Title: 89Zr-DFO-girentuximab (TLX250-CDx): Evaluation of radiation dosimetry, safety, and optimal imaging parameters in Chinese patients with indeterminate renal masses (ZIRDOSE-CP) 

Presenter: Shams Arifeen, Telix 

Date and Time: Sunday 28 April, 2024 | 2:15 pm – 2.30 pm (NZT) 

Session: Across the Motu/Country Session 

Format: Oral Presentation 

Location: Te Pae Auditorium ID: NCT05861778 

Breakfast Session and Nurses Workshop 

Telix Hosted Breakfast 

Location: Dobson 4 

Date and Time: Saturday 27 April, 2024 | 7:00 am – 8:15 am (NZT) 

Topics and Presenters: 

  • An introduction to antibody targets and the potential role of rADCs as a new drug class in the management of prostate cancer – Michael Wheatcroft, Telix 
  • Transforming management of kidney cancer: imaging and therapy approaches with radiolabelled girentuximab – Professor Andrew Scott AM, Olivia Newton-John Cancer Research Institute, Austin Hospital, Melbourne, Australia 
  • Advancing inclusive prostate cancer care: Extending the reach of mobile PSMA-PET/CT to local, regional, and remote communities across Aotearoa/New Zealand – Madhusudan Vyas, Mercy Radiology, New Zealand 
  • Role of AI in Theranostics – Simon Wail, Telix 

Breakfast attendance is free! Register via the main conference website:   

Nurses Workshop, Providing Optimal Care in Radiotheranostics 

Location: Dobson 3 

Date and Time: Saturday 27 April, 2024 | 1:30 pm – 3:30 pm (NZT) 

Topics and Presenters: 

  • Understanding radiopharmaceuticals and tumour microenvironment effects – Michael Wheatcroft, Telix 
  • Navigating side effects (tips and tricks) – Elizabeth Medhurst (Nurse Consultant, Prostate) and Kate Wakelin (Nurse Consultant, Neuroendocrine Tumours), Peter MacCallum Cancer Centre, Melbourne, Australia 
  • Working within a multidisciplinary team: Managing patients from pre- to post-imaging and therapy – Elizabeth Medhurst 
  • Difficult conversations: Addressing patient selection, treatment challenges, and expectations – Kate Wakelin 

Illuccix® has been approved by the U.S. Food and Drug Administration (FDA), by the Australian Therapeutic Goods Administration (TGA), and by Health Canada. No other Telix product has received a marketing authorisation in any jurisdiction. Zircaix® brand name is subject to final regulatory approval.